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Abstract
In various populations worldwide, common variants of the TCF7L2 (Transcription factor 7-like 2) gene are associated
with the risk of type 2 diabetes mellitus (T2DM). The aim was to investigate the association between rs12255372
(G/T) polymorphism in the TCF7L2 gene and T2DM in an Iranian population. 236 unrelated patients with T2DM, and
255 normoglycemic controls without diabetes were studied. The PCR-RFLP method was used for genotyping
rs12255372 (G/T) polymorphism, and the SPSS version 18.0 for Windows for statistical analysis. The minor T allele
of TCF7L2 rs12255372 was found to significantly increase the risk of T2DM, with an allelic odds ratio (OR) of 1.458
(95% CI 1.108-1.918, p = 0.007). A significant difference in TT genotype was observed between T2DM patients and
normoglycemic controls (OR 2.038, 95% CI 1.147-3.623; p = 0.014). On assuming dominant and recessive models,
ORs of 1.52 [95% CI (1.05-2.21) p = 0.026)] and 1.74 [95% CI (1.01-3.00) p = 0.043] were obtained, respectively,
thereby implying that the co-dominant model would best fit the susceptible gene effect. This study further confirms
the TCF7L2 gene as enhancing susceptibility to the development of T2DM.
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Introduction
Type 2 diabetes mellitus (T2DM) is a heterogeneous
metabolic disorder arising from the interplay of genetic and
environmental factors (Barroso, 2005). Diabetes and its as-
sociated complications pose a major health-care burden
worldwide, presenting major challenges to patients
well-being, health-care systems and national economies
(Ramachandran et al., 2010). Although the prevalence of
T2DM worldwide is about 6%, it is likely to rise over the
next decade, due to the increasing age of the population,
and surge of obesity (Zimmet, et al., 2001). Accounting for
90~95% of populations with diabetes, T2DM is predicted
to reach 300 million people worldwide by the year 2025
(Zimmet et al., 2001; Grant et al., 2006;). There are signifi-
cant geographic and racial differences in incidence, this
ranging from 4.6 to 40% in the Middle East (Al-Nuaim,
1997; Abdella et al., 1998; Husseini et al., 2000; Al-Habori
et al., 2004), 1.2% to 14.6% in Asia, and 1.3% to 14.5% in
Iran (Azizi et al., 2003a,b).
The transcription factor 7–like 2 gene (TCF7L2), also
known as TCF-4, is a nuclear receptor for CTNNB1 (previ-
ously known as -catenin), which in turn mediates the ca-
nonical WNT signaling pathway (Polakis, 2000; Smith,
2007). Recent genome-wide association studies have dra-
matically increased knowledge on the genetic background
of T2DM. Intronic variants of the TCF7L2 gene, besides
having been set forth as possible genetic risk factors for
T2DM, have also been associated with alterations in the
function of beta cells among normoglycemic individuals
(Bonetti et al., 2011). Current evidence presupposes that
the predominant effect of TCF7L2 dysfunction on type 2
diabetes development may be mediated through the impair-
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ment of insulin secretion (Damcott et al., 2006; Florez et
al., 2006; Saxena et al., 2006; Scott et al., 2006; Chandak et
al., 2007). Grant and colleagues have reported the associa-
tion of a common microsatellite (DG10S478) within intron
3 of TCF7L2 with T2DM. They showed that allele G of
SNP rs12255372 is in strong linkage disequilibrium (LD)
with allele 0 of DG10S478, as allele T of rs12255372 is
with other alleles of DG10S478 (Grant et al., 2006).
There are at least four well-studied polymorphic
markers in the humanTCF7L2 gene, which are associated
with T2DM, viz., rs7903146, rs7901695, rs12255372 and
rs11196205. Most published epidemiological studies have
placed emphasis on rs7903146 (C/T) and rs12255372
(G/T) variations (Luo et al., 2009; Tong et al., 2009), with
the consequential association of rs7903146 TCF7L2 poly-
morphism with T2DM (Amoli et al., 2010).
In this study, the aim was to investigate the associa-
tion between the TCF7L2 rs12255372 variant and T2DM in
an Iranian population. To our knowledge, this SNP has not
been previously tested in the Iranian population.
Subjects and Method
Subjects
The studied population comprised 236 unrelated
T2DM patients and 255 normoglycemic controls without
diabetes. The T2DM patients were recruited from the
Gorgan Clinic of Diabetes, Golestan University of Medical
Sciences, north Iran. The normoglycemic controls, re-
cruited from the same area, were age-matched with the case
population. T2DM-patient diagnosis, based on the standard
criteria (American Diabetes Association, 2004), with fast-
ing plasma glucose  126 mg/dL, 2-h plasma glucose 
200 mg/dL during an oral glucose tolerance test. Written in-
formed consent was obtained from each subject. Patients
with the age-of-onset < 37 years were excluded. All those
selected for this study were of Fars origin.
Clinical characteristics
Anthropometric measurements of weight, height and
waist-circumference were obtained by standardized tech-
niques. The body mass index (BMI) was calculated as the
weight in kilograms divided by the square of the height in
meters. HbA1c levels were defined by using turbidometric
inhibition immunoassaying (Tina Quant, Roche, Basel,
Switzerland).
BMI, waist circumference and HbA1c were mea-
sured in T2DM patients and normoglycemic controls.
DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood
leukocytes using the phenol/chloroform procedure. The
study was approved by the Ethics committee of Golestan
University of Medical Sciences (No: 1090). The
rs12255372 polymorphism was genotyped using the PCR-
RFLP method. Briefly, the region was amplified with the
following primers: Forward 5’- CTG GAA ACT AAG
GCG TGA GG -3’; Reverse 5’- GGG TCG ATG TTG TTG
AGC TT -3’. The PCR cycles were as follows: 5 min at
94 °C, followed by 35 cycles of 30 s at 94 °C, 30 s at 54 °C
and 30 s at 72 °C. Final extension was for 10 min at 72 °C.
Subsequently, 10 L of the 346 bp amplified product was
digested with the TsaI (Tsp509I) restriction enzyme (Fer-
mentas, EU) for 3 h at 65 °C. After treatment with restric-
tion enzymes, amplicons were subjected to 3.5% agarose
gel electrophoresis and stained with ethidium bromide. The
studied region usually has two restriction sites, the G  T
allele change creating a new one. Some genotyping results
were validated by direct sequencing.
Statistical analysis
Data analysis was with SPSS Statistical software
(version 18, SPSS, Chicago, IL, USA). A P value of < 0.05
was considered as significant. Mean  SD and relative fre-
quency were used for quantitative and qualitative traits, re-
spectively. The SHAPIRO-WILK test was applied to
diabetic and normoglycemic subjects, to compare normal-
ity of quantitative traits in both groups, the mean of these
traits being subsequently compared by t-testing. The asso-
ciation of SNPs with T2DM in matched case-control sub-
jects was tested using 2 analysis, as well as the calculation
of Odds ratios (ORs), with 95% confidence intervals (CIs).
Results
A case-control association study was undertaken,
comprising 236 T2DM patients and 255 normoglycemic
controls, all over 37 years-of-age. 35 subjects (20 normo-
glycemic controls and 15 T2DM patients) were excluded,
through unavailability of individual genomic DNA, thus
leaving 221 T2DM patients and 235 normoglycemic con-
trols for genotyping. Genotype frequencies did not differ
from the expected Hardy-Weinberg ratios.
The minor T allele of the TCF7L2 rs12255372 was
found to significantly increase T2DM risk, with an allelic
odds ratio (OR) of 1.458 (95% CI 1.108-1.918, p = 0.007)
in the population under study. T allele frequency was
38.7% in T2DM patients and 30.2% in normoglycemic
controls (Table 1).
A comparison of genotype frequencies in T2DM pa-
tients and normoglycemic controls showed a significant
difference in the frequency of the TT genotype (OR 2.038,
95% CI 1.147-3.623; p = 0.014), although not so in the GG
and GT genotypes (Table 1).
To investigate which model would fit the effect of
TCF7L2 rs12255372, dominant and recessive models were
considered. In the dominant model (GG vs. TT and GT), the
genotype frequencies were compared between the T2DM
and control groups and a significant association with
T2DM was observed (OR 1.52, 95% CI (1.05-2.21)
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p = 0.026). Assuming the recessive model (GG and GT vs.
TT), a significant association was also found (OR 1.74,
95% CI (1.01-3.00) p = 0.043). Thus, the highest risk was
observed under the co-dominant model (OR 2.038, 95% CI
(1.147-3.623) p = 0.014) (Table 1).
Based on rs12255372 (GT) genotypes, the clinical
and biochemical characteristics of the T2DM patients and
normoglycemic individuals were stratified. With the ex-
ception of waist circumference, which was significantly
higher in G allele homozygotes (p = 0.002), no association
was found between this variant and either age, BMI or
HbA1c in T2DM patients (Table 2). Comparative analyses
of normoglycemic controls and rs12255372 (G/T) geno-
types also revealed no association of clinical characteristics
with the genotype (data not shown).
Discussion
In this study, the aim was to explore the association of
TCF7L2 rs12255372 polymorphism with Type 2 diabetes
(T2DM) in an Iranian population. We found that the minor
T allele of TCF7L2 rs12255372 significantly increases
T2DM risk, with an allelic odds ratio (OR) of 1.458 (95%
CI 1.108-1.918, p = 0.007) (Table 1). Although the stron-
gest association with T2DM risk in most reported studies is
with rs7903146, some studies have shown a stronger asso-
ciation with rs12255372 (Scott et al., 2006; Chandak et al.,
2007; Hayashi et al., 2007; Wang et al., 2007; Saadi et al.,
2008).
However, no association between a TCF7L2
rs12255372 variant and T2DM has been reported in Chi-
nese, Arabic and Pima Indian populations (Chang et al.,
2007; Guo et al., 2007; Alsmadi et al., 2008;). Furthermore,
a modest association of TCF7L2 rs12255372 with T2DM
was shown in an African-American population (Sale et al.,
2007). The underlying mechanisms, by which genetic vari-
ation within the intron of the TCF7L2 gene confers suscep-
tibility to type 2 diabetes, remain to be elucidated. Genetic
variations near the 3’ end of the TCF7L2 gene may affect
the action of TCF7L2, through the regulation of alternative
splicing (Chang et al., 2007).
Frequency of the minor T allele in the normogly-
cemic controls was found to be 30.2%, thus, although con-
sistent with Palestinian, Amish and French populations
(29.3, 29, and 30%, respectively) (Cauchi et al., 2006;
Damcott et al., 2006; Ereqat et al., 2010), quite different
from that reported in a Chinese population (3%) (Ren et al.,
2008). The frequency of the TT genotype carrying the two
minor alleles (risk alleles) was significantly different in
T2DM patients compared to normoglycemic controls,
thereby implying a possible gene dosage effect. However,
although the frequency of the GT genotype was higher in
the T2DM patients compared to normoglycemic controls,
no significant difference was observed between GT geno-
types and T2DM.
To determine whether there is any interaction be-
tween rs12255372 (G/T) genotypes and clinical and bio-
chemical characteristics, the association between geno-
types and covariates in T2DM patients and normoglycemic
controls was studied separately. Although no association
was found between the variant and age, BMI and HbA1c in
T2DM patients, in an earlier study of Emirati subjects
(Saadi et al., 2008), waist circumference was found to be
significantly higher in G allele homozygotes.
The study proved the rs12255372 variant of the
TCF7L2 gene to be associated with T2DM in the Iranian
population, in contrast with previous reports on Chinese,
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Table 1 - The TCF7L2 rs12255372 polymorphism allele and genotype frequencies in T2DM patients and normoglycemic controls.
Genotype normoglycemic controls (n = 235) T2DM * patients (n = 221) OR (95% CI) p value†
GG (%) 118 (50.2) 88 (39.8) - -
GT (%) 92 (39.1) 95 (42.9) 1.385 (0.930-2.061) 0.109
TT (%) 25 (10.6) 38 (17.1) 2.038 (1.147-3.623) 0.014
G allele (%) 328 (69.8) 271 (61.3) - -
T allele (%) 142 (30.2) 171 (38.7) 1.458 (1.108-1.918) 0.007
*Type 2 diabetes mellitus. †A p value of < 0.05 was considered as significant.
Table 2 - Clinical characteristics of the T2DMM subjects stratified by rs12255372 (G/T) genotypes.
Variable GG GT TT p value
Age (years) 52.40  7.32 51. 29  10.68 51.61  11.68 0.741
Waist circumference(cm) 104.54  13.29 97.87  11.92 99.68  10.99 0.002
BMI (kg/m2) 29.82  5.10 29. 15  4.75 28.88  5.51 0.34
HbA1C 8.75  1.93 9.00  2.19 8.73  2.05 0.656
Arab and Pima Indian populations. According to the con-
clusions divulged in a recently published meta-analysis
(Tong et al., 2009), the magnitudes of this association are
moderate. TT homozygous variants would approximately
cause a 1.9-fold increase in T2MD as concluded by results
of many studies, a value that is lesser but still close to our
own result (OR = 2.038). A possible explanation for this in-
congruity could be differences in ethnic background, or the
effects of environmental factors, such as life-style. Further
studies are required to clarify the exact mechanism of its ef-
fect.
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